Ovarian cancer: Current outlook on this deadly disease

Postgraduate Medicine

Volumn 102, Issue 3, 1997, Pages 112-120

  Nahhas, William A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTRETAMINE; ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MEGESTROL ACETATE; PACLITAXEL; TAMOXIFEN CITRATE; TOPOTECAN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; FEMALE; FOLLOW UP; HUMAN; OVARY CANCER;

EID: 0030967866     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.09.311     Document Type: Conference Paper

References (17)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47(1):5-27
2. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 Pt 2):S4-14
3. Lynch HT, Lynch JF. Hereditary ovarian carcinoma. Hematol Oncol Clin North Am 1992;6(4):783-811
4. DePriest PD, Shenson D, Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol 1993;51(1):7-11
5. DePriest PD, van Nagell JR Jr, Gallion HH, et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51(2):205-9
6. Caruso A, Caforio L, Testa AC, et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol 1996;63(2):184-91
7. Bourne TH, Campbell S, Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993;306(6884):1025-9
8. Gallion HH, Powell DE, Morrow JK, et al. Molecular genetic changes in human epithelial ovarian malignancies. Gynecol Oncol 1992;47(2):137-42
9. Hoskins WJ, Rubin SC. Surgery in the treatment of patients with advanced ovarian cancer. Semin Oncol 1991;18(3):213-21
10. McGuire WP. Primary treatment of epithelial ovarian malignancies. Cancer 1993;71(4 Suppl):1541-50
11. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170(4):974-9; discussion, 979-80
12. Qazi F, McGuire WP. The treatment of epithelial ovarian cancer. CA Cancer J Clin 1995;45(2):88-101
13. Massad LS Jr, Hunter VJ, Szpak CA, et al. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol 1991; 78(6):1027-32
14. Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45(2):71-87
15. Nguyen HN, Averette HE, Hoskins W, et al. National Survey of Ovarian Carcinoma Part V: the impact of physician's specialty on patients' survival. Cancer 1993;72(12):3663-70
16. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334(1):1-6
17. Vergote IB, Vergote-De Vos LN, Abeler VM, et al. Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer. Cancer 1992;69(3):741-9